Willmar Schwabe India Resorcinum 6X (20g) : For vomiting, lumbago, muscular & joint pain, constipation, appendicitis

89

Also known as

resorci

Properties

Potency

6X

Weight

75 (gms)

Dimensions

measuring 3.2 by 3.2 by 6.7 centimeters

Willmar Schwabe India Resorcinum

Uses of Willmar Schwabe India Resorcinum

  • Resorcinum effectively reduces summertime complaints of nausea and vomiting
  • It promotes early healing by assisting in the destruction of organic putrification germs.
  • It treats tympanites, right iliofemoral pain, and constipation.
  • These tablets provide relief from rheumatic symptoms, particularly joint pain and stiffness.

Common symptoms of Willmar Schwabe India Resorcinum

  • Acute rheumatism, lumbago, chest pain, and muscular pain are all effectively relieved.
  • With the aid of Resorcinum, abdominal pain and excessive gas buildup are alleviated.

Reactions while taking Willmar Schwabe India Resorcinum

Since homeopathic medicines do not affect the effects of other medications, such as those from allopathy or ayurveda, it is safe to take the tablets even if you are taking other forms of treatment.

Dosage of Willmar Schwabe India Resorcinum

Dissolve tablets under the tongue after placing them in your mouth.

Twelve-year-olds and older adults should take two tablets, twice daily, or as directed by their doctor.

One to two doses per day for chronic afflictions.

If symptoms do not disappear, reduce the dosage; if they do not, see a doctor.

Precautions while taking Willmar Schwabe India Resorcinum

Never take medication within 15 minutes of eating or drinking.

Consult a homeopathic doctor prior to use if you are pregnant or nursing.

While taking medication, refrain from consuming alcohol or tobacco.

Terms and Conditions

Before purchasing this medication, we have assumed that you sought medical advice and are not using it for self-medication.

Attributes
BrandDr. Willmar Schwabe India
Remedy TypeHomeopathic
Country of OriginIndia
Homeo FormsBiochemic Tablet
Potency6X
Price₹ 110

Comments are closed.